AbbVie
ABBV
3,140 hedge funds and large institutions have $197B invested in AbbVie in 2023 Q1 according to their latest regulatory filings, with 158 funds opening new positions, 1,251 increasing their positions, 1,360 reducing their positions, and 117 closing their positions.
55% more call options, than puts
Call options by funds: $3.15B | Put options by funds: $2.04B
35% more first-time investments, than exits
New positions opened: 158 | Existing positions closed: 117
0.07% less ownership
Funds ownership: 69.85% → 69.77% (-0.07%)
1% less funds holding
Funds holding: 3,169 → 3,140 (-29)
8% less repeat investments, than reductions
Existing positions increased: 1,251 | Existing positions reduced: 1,360
13% less funds holding in top 10
Funds holding in top 10: 348 → 303 (-45)
23% less capital invested
Capital invested by funds: $255B → $197B (-$58.3B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
+$1.91B |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$660M |
| 3 |
Amundi
Paris,
France
|
+$381M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$329M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$273M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$665M |
| 2 |
JP Morgan Chase
New York
|
-$460M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$435M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$418M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
-$324M |
ABBV Hedge Fund Activity: Q1 2023 in Review
3,140 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2023, worth a combined $197B — down 23% from $255B a quarter earlier.
Buyers outnumbered sellers: 158 funds opened new ABBV positions and 117 closed out — a net gain of 41 holders — while 1,251 added to existing stakes and 1,360 trimmed.
The largest buyer was Charles Schwab, adding an estimated $1.91B. The largest seller was Capital International Investors, cutting an estimated $665M.
- 3,140 institutional investors held AbbVie (ABBV) as of Q1 2023, down from 3,169 in Q4 2022.
- Funds reported $197B of AbbVie stock for Q1 2023, down 23% quarter-over-quarter.
- 158 funds opened new AbbVie positions in Q1 2023 and 117 closed out, a net change of +41 holders.
- The largest AbbVie buyer in Q1 2023 was Charles Schwab, an estimated $1.91B added.
- The largest AbbVie seller in Q1 2023 was Capital International Investors, an estimated $665M sold.
Based on aggregated 13F filings for Q1 2023.